Read by QxMD icon Read


A Haylett, D Koumaki, L E Rhodes
BACKGROUND: Solar urticaria (SU) is a rare chronic inducible urticaria triggered via uncharacterised chromophores. We detail responses of a large patient series to monochromator phototesting and broadband ultraviolet radiation (UVR); relationship to life quality is explored. METHODS: Retrospective review of all SU patients undergoing standardised diagnostic photoinvestigation at a specialist centre during 2000-2016. From 2011, patients completed dermatology life quality index (DLQI) questionnaires for the past week and year...
March 13, 2018: Photodermatology, Photoimmunology & Photomedicine
Giovanni Damiani, Chiara Franchi, Paolo Pigatto, Andrea Altomare, Alessia Pacifico, Stephen Petrou, Sebastiano Leone, Maria Caterina Pace, Marco Fiore
AIM: To evaluate the outcomes in biological treatment and quality of life of psoriatic patients with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) compared to pegylated interferon-2α plus ribavirin (P/R) therapy. METHODS: This is a retrospective study involving psoriatic patients in biological therapy who underwent anti-hepatitis C virus (HCV) treatment at the Department of Dermatology Galeazzi Orthopaedic Institute Milan, Italy from January 2010 to November 2017...
February 27, 2018: World Journal of Hepatology
Flora N Balieva, Andrew Y Finlay, Jörg Kupfer, Lucía Tomas Aragones, Lars Lien, Uwe Gieler, Françoise Poot, Gregor B E Jemec, Laurent Misery, Lajos Kemeny, Francesca Sampogna, Henriët van Middendorp, Jon Anders Halvorsen, Thomas Ternowitz, Jacek C Szepietowski, Nikolay Potekaev, Servando E Marron, Ilknur K Altunay, Sam S Salek, Florence J Dalgard
Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%)...
March 2, 2018: Acta Dermato-venereologica
Melissa L F Knuckles, Eugenia Levi, Jennifer Soung
PURPOSE: Patients with moderate plaque psoriasis are often undertreated and may experience unsatisfactory clinical outcomes. Undertreatment may stem partly from a lack of consensus on the definition of moderate psoriasis and appropriate treatments for patients with moderate disease severity. MATERIALS AND METHODS: An online survey was conducted during October 2015 to determine how US dermatologists in the clinical setting define and treat moderate psoriasis. RESULTS: A total of 150 dermatologists responded to the survey (mean time in practice: 13...
March 5, 2018: Journal of Dermatological Treatment
Liang Cai, Sakae Kaneko, Eishin Morita
Stress-induced scratching is an issue in patients with adult atopic dermatitis (AD). Symptoms of stress-induced AD are common in clinical practise. Salivary chromogranin A (CgA) level has research value as a possible index related to a patient's psychological stress. Using saliva, which is easily collectable, we compared two assessments of the severities of AD and stress with the levels of stress proteins in the saliva of 30 patients with AD in the Department of Dermatology of Shimane University between April 2015 and May 2017...
March 3, 2018: Journal of Dermatology
Farah Asad, Moosa Khan, Fatima Rizvi
Objectives: To evaluate the effect of Atorvastatin as an adjuvant with betamethasone valerate on disease severity and cardiovascular risks in chronic plaque type psoriatic patients. Methods: It is an interventional study conducted in Pharmacology Department of BMSI, JPMC with the collaboration of Dermatology Department of JPMC, Karachi. The duration of study was from June 2013 to June 2016. Seventy five psoriatic patients were prescribed Tablet Atorvastatin 40-20 mg/day (40mg for first three months twice daily followed by 20mg once daily for the next three month) plus topical Betamethasone Valerate 0...
November 2017: Pakistan Journal of Medical Sciences Quarterly
K A Papp, K B Gordon, R G Langley, M G Lebwohl, A B Gottlieb, S Rastogi, R Pillai, R J Israel
BACKGROUND: Biologics used increasingly used for treating moderate-to-severe psoriasis. Efficacy may differ in patients with previous biologics exposure. OBJECTIVE: To investigate the impact of previous biologic exposure on efficacy and safety of brodalumab and ustekinumab in moderate-to-severe plaque psoriasis. METHODS: Two placebo- and ustekinumab-controlled phase 3 clinical trials. Initial 12-week induction phase where patients were treated with brodalumab (210mg Q2W or 140mg Q2W), ustekinumab or placebo...
February 28, 2018: British Journal of Dermatology
J Marcelino, A C Costa, A Mendes, E Alonso, F Cabral Duarte, E Pedro, M Pereira-Barbosa
Objective. Describe the safety and long-term use of omalizumab in chronic urticaria (CU), both spontaneous (CSU) and inducible (CIndU). Methods. Retrospective chart-review (2006-15) of CU patients treated with omalizumab for ≥ 6 months. Statistical analyses: descriptive statistics, Mann-Whitney, generalized linear models. Results. 23 patients with CSU (3 men), 3 with CIndU (2 men). Generalized linear models showed UAS reduction per omalizumab administration of 16% in CIndU and CSU and UAS7, of 15% in CIndU, and 20% in CSU...
January 16, 2018: European Annals of Allergy and Clinical Immunology
Fa-Ping Wang, Xiao-Ju Tang, Chuan-Qi Wei, Lin-Rui Xu, Hui Mao, Feng-Ming Luo
BACKGROUND: Dupilumab, a fully human monoclonal antibody against the interleukin-4-receptor α subunit, has been developed and used in clinical trials to treat atopic dermatitis (AD). OBJECTIVE: We aimed to assess the overall efficacy and safety of dupilumab treatment in AD. METHODS: PubMed, Embase, Cochrane library databases, and the Chinese Biological Medicine (CBM) published up to September 2017 were searched. All randomized controlled trials (RCTs) of dupilumab treatment on adult patients with AD were included...
February 19, 2018: Journal of Dermatological Science
Linda Stein Gold, Jerry Bagel, Mark Lebwohl, J Mark Jackson, Rongdean Chen, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin
<p>BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in systemic-naive patients with chronic moderate plaque psoriasis with lower psoriasis-involved body surface area (BSA; 5%-10%) during the 16-week, double-blind, placebo-controlled phase. We describe efficacy and safety of apremilast in this population through week 52 in UNVEIL.</p> <p>METHODS: Patients with moderate plaque psoriasis (BSA 5%-10%; static Physician's Global Assessment [sPGA] score of 3 [moderate]) and naive to systemic therapies for psoriasis were randomized (2:1) to receive apremilast 30 mg twice daily or placebo for 16 weeks...
February 1, 2018: Journal of Drugs in Dermatology: JDD
Gordon Sussman, Mohamed Abuzakouk, Frédéric Bérard, Walter Canonica, Hanneke Oude Elberink, Ana Giménez-Arnau, Clive Grattan, Kelly Hollis, Shannon Hunter, André Knulst, Jean-Philippe Lacour, Charles Lynde, Alexander Marsland, Doreen McBride, Marcus Maurer, Alla Nakonechna, Javier Ortiz de Frutos, Maria Reynolds, Carolyn Sweeney, Haijun Tian, Karsten Weller, Daniel Wolin, Maria-Magdalena Balp
BACKGROUND: ASSURE-CSU revealed differences in physician and patient reporting of angioedema. This post-hoc analysis was conducted to evaluate the actual rate of angioedema in the study population and explore differences between patients with and without angioedema. METHODS: This international observational study assessed 673 patients with inadequately controlled chronic spontaneous urticaria (CSU). Physicians abstracted angioedema data from medical records, which were compared with patient-reported data...
February 20, 2018: Allergy
Punyawee Ongsri, Sumanas Bunyaratavej, Charussri Leeyaphan, Penvadee Pattanaprichakul, Pattachee Ongmahutmongkol, Chulaluk Komoltri, Kanokvalai Kulthanan
Background: Superficial fungal foot infection is one of the most important dermatological diseases currently affecting military personnel. Many Thai naval rating cadets are found to suffer from superficial fungal foot infections and their sequels. Objective: To investigate prevalence, potent risk factors, responding pathogens and clinical correlation of superficial fungal foot infection in Thai naval rating cadets training in Naval rating school, Sattahip, Thailand...
February 13, 2018: Military Medicine
R Bissonnette, T Luger, D Thaçi, D Toth, A Lacombe, S Xia, R Mazur, M Patekar, P Charef, M Milutinovic, C Leonardi, U Mrowietz
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favorable safety profile in the treatment of moderate to severe psoriasis and psoriatic arthritis. OBJECTIVE: To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate to severe psoriasis. METHODS: In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1...
February 14, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
Gerardo Rosati, Carmine Pinto, Francesca Di Fabio, Silvana Chiara, Ivan R Lolli, Enzo M Ruggeri, Libero Ciuffreda, Raimondo Ferrara, Lorenzo Antonuzzo, Daniela Adua, Patrizia Racca, Domenico Bilancia, Elena Benincasa, Maria Elena Stroppolo, Francesco Di Costanzo
OBJECTIVES: The influence of age (<70 years and ≥70 years) was retrospectively studied on the quality of life (QoL), incidence of side effects (including skin reactions) and efficacy of chemotherapy plus cetuximab in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC). METHODS: 225 patients of the Observed study (PS 0-1) were retrieved based on age (< 70 and ≥70 years) and evaluated through EORTC QLQ-C30 and DLQI questionnaires...
February 9, 2018: Journal of Geriatric Oncology
S W Youn, J-H Lee, D Y Yu, Y Kim, B S Kim, S J Seo, Y B Choe, S-K Yun, J Park, N I Kim, C W Choi, J I Youn, S-J Lee, M-G Lee, K J Kim, C J Park, Y S Ro, H J Song, B S Shin, S K Ahn, J Y Lee, Y H Won, M S Jang, K H Kim, M H Kim, T Y Kim, J H Choi
BACKGROUND: Psychological aspect and quality of life should be considered in treating patients with psoriasis. OBJECTIVE: We sought to ascertain which clinical characteristics including presence of exposed lesions are associated with impairment of health-related quality of life (HRQoL) in patients with psoriasis. METHODS: The EPI-PSODE study was a nationwide, multicenter, cross-sectional study conducted in Korea that included 1,260 adult patients with psoriasis...
February 11, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
Mathias Tiedemann Svendsen, Flemming Andersen, Kirsten Hammond Andersen, Klaus Ejner Andersen
BACKGROUND: Topical corticosteroid or corticosteroid/calcipotriol preparations are recommended first-line topical treatments of psoriasis, but a main cause for the lack of efficacy of topical treatments is considered low rates of adherence to topical drugs. Patient support by the use of applications (apps) for smartphones is suggested to improve medical adherence. METHODS/DESIGN: Design: An investigator-initiated, single-center, single-blind, parallel-group, phase-4 clinical superiority randomized controlled trial (RCT)...
February 7, 2018: BMC Dermatology
D Rigopoulos, D Ioannides, G Chaidemenos, P Kallidis, A Voultsidou, A Matekovits, E Soura
"The Protimisis" study was a multicenter, cross-sectional study investigating the relative importance and economic value that patients assign to different characteristics of systemic psoriasis treatments. Treatment preferences were investigated with the DCE methodology and patients had to decide over the most important aspects of different psoriasis treatments. A questionnaire regarding demographic data/medical history and the DLQI and EQ-5D-3L questionnaires were also completed. A total of 310 patients were included...
February 6, 2018: Dermatologic Therapy
Andreas Körber, Charis Papavassilis, Vaishali Bhosekar, Maximilian Reinhardt
BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis. AIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects...
February 5, 2018: Drugs & Aging
Joseph F Fowler, James Q Del Rosso, Refika I Pakunlu, Srinivas Sidgiddi
Objective: To assess patient-reported satisfaction, efficacy, and tolerability associated with the use of betamethasone dipropionate spray 0.05% when applied twice daily in subjects with moderate plaque psoriasis. Design: This was an open-label, multicenter study involving 45 patients with moderate plaque psoriasis, with the aim of evaluating patient-reported outcomes with betamethasone dipropionate spray 0.05%. Patients treated all affected areas twice daily with betamethasone dipropionate (BD) spray 0.05% for 28 days per label instructions...
November 2017: Journal of Clinical and Aesthetic Dermatology
L Misery, E Jourdan, F Huet, E Brenaut, B Cadars, S Virassamynaïk, M Sayag, C Taieb
BACKGROUND: Many epidemiological studies have been performed, but a potential increase in the prevalence of sensitive skin as well as its relationship with age and skin type and the impact of sensitive skin on quality of life are still debated. OBJECTIVE: TO ANSWER THESE UNRESOLVED QUESTIONS: METHODS: An opinion poll was conducted on a representative French 5000-person sample. RESULTS: Fifty-nine percent of the people declared very sensitive or fairly sensitive skin (together: sensitive skin), and women (66%) declared sensitive skin more frequently than men (51...
February 3, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"